VectivBio Holding AG is a biopharmaceutical company that develops and commercializes medicines for severe rare conditions. Its focus is on developing apraglutide, a synthetic peptide analog for the treatment of short bowel syndrome-intestinal failure and steroid-refractory gastrointestinal acute versus host disease. The company was founded in 2019 and is headquartered in Basel, Switzerland.